Alnylam Pharmaceuticals
ALNY
#565
Rank
โ‚ฌ33.36 B
Marketcap
255,92ย โ‚ฌ
Share price
-0.36%
Change (1 day)
85.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): -1,79ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -1,74ย โ‚ฌ. In 2023 the company made an earnings per share (EPS) of -3,13ย โ‚ฌ an increase over its 2022 EPS that were of -8,23ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)-1,79ย โ‚ฌ
2023-3,13ย โ‚ฌ-62%
2022-8,23ย โ‚ฌ29.03%
2021-6,37ย โ‚ฌ-3.36%
2020-6,60ย โ‚ฌ-8.48%
2019-7,21ย โ‚ฌ7.67%
2018-6,69ย โ‚ฌ39.74%
2017-4,79ย โ‚ฌ12.94%
2016-4,24ย โ‚ฌ38.84%
2015-3,05ย โ‚ฌ-32.88%
2014-4,55ย โ‚ฌ259.44%
2013-1,27ย โ‚ฌ-31.25%
2012-1,84ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-0,89ย โ‚ฌ-48.47%๐Ÿ‡บ๐Ÿ‡ธ USA
36,97ย โ‚ฌ-2,230.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-2,24ย โ‚ฌ 29.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,04427ย โ‚ฌ-97.45%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,65ย โ‚ฌ-62.76%๐Ÿ‡บ๐Ÿ‡ธ USA
5,69ย โ‚ฌ-428.06%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2,52ย โ‚ฌ-245.49%๐Ÿ‡ซ๐Ÿ‡ท France
-1,01ย โ‚ฌ-41.84%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel